A

Amgen

Makes biotech medicines for serious illnesses

Regulatory Lead

Full-TimeUpdated on 10/24/2026
$112.7k - $152.5k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Mid
Bachelor's, Master's, PhD, Associate's
Remote in USA
Remote
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A doctorate degree; or a master’s degree and 3 years of US Regulatory experience; or a bachelor’s degree and 5 years of US Regulatory experience; or an associate’s degree and 10 years of US Regulatory experience; or a high school diploma or GED and 12 years of US Regulatory experience.
  • In addition to one of the listed education and experience combinations, experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources is required; managerial experience may run concurrently with the required technical experience.
Responsibilities
  • Assist in aligning local regulatory requirements with Amgen’s corporate standards.
  • Provide local input to and execute regulatory strategies.
  • Plan and manage local regulatory submissions in compliance with corporate standards and local regulatory requirements.
  • Provide guidance on local mechanisms to optimize product development and regulatory approvals.
  • Ensure local labels are developed and maintained in line with local legislation and Amgen standards and procedures.
  • Ensure and support local regulatory product compliance, including IMR, PMCs, and agency commitments.
  • Act as the point of contact with regulatory agencies.
  • Support and provide input into the global regulatory strategy for assigned products, including Global Regulatory Strategic Plans and labeling documents.
  • Contribute to the filing plan for marketing authorization and lifecycle maintenance, advising and discussing with the local cross-functional team.
  • With general supervision, execute the filing plan for marketing authorization and lifecycle maintenance for assigned countries, where applicable.
  • Ensure regulatory submissions are made on time and meet Amgen’s corporate and local regulatory requirements.
  • Create, review, and approve source text for country labeling, and own country artwork based on source text.
  • Collaborate with Regional and Global Study Operations teams to support local planning and execution for clinical studies in accordance with national legal and regulatory requirements, where appropriate.
  • Review and approve promotional and non-promotional materials.
  • Monitor changes in local trade associations and national legislation, and communicate information and its impact to local and regional groups.
  • Monitor the external regulatory environment to help inform and advise regulatory decision-making.
  • Ensure and support regulatory product compliance, including IMR, PMCs, pediatric, and other agency commitments.
  • Manage regulatory submissions of urgent safety communications, DHPCs, and DILs as required by Amgen standard operating procedures or local regulatory requirements.
  • Advise Global teams on local regulatory implications and requirements relevant to global clinical development and marketing application plans and objectives.
  • As part of the Global Regulatory Team, provide regulatory direction and expertise on local regulatory mechanisms to optimize product development, including expediting studies, Orphan Drug Designations, expedited regulatory designations, compassionate use, and pediatric plans.
  • Act as the point of contact with regulatory agencies in fulfilling local obligations.
  • Participate in and contribute to local agency interactions and their preparation.
  • Work closely with cross-functional colleagues in the country, Affiliate, or Hub to align strategy and deliver country, Affiliate, or Hub goals.
  • Exchange regulatory information and intelligence with regulatory colleagues and cross-functional teams on an ongoing basis, and provide timely advice on local regulatory considerations and regulations.
  • Partner with International Regulatory Leads and Global Regulatory Leads to support regulatory development, registration, and lifecycle management of Amgen molecules.
  • Partner with peers to ensure consistency in procedures.
  • Act as a contact and build relationships with agency staff for assigned products, if applicable.
  • Establish regular contacts and interactions with distributors, if applicable.
  • Provide subject matter expert support to process improvement projects and initiatives.
  • Assist locally in healthcare compliance activities, where applicable.
  • Participate in local regulatory process improvements, initiatives, and training.
  • Oversee external vendor and contractor relationships, where applicable.
  • Assist locally in healthcare compliance, quality assurance, or pharmacovigilance activities, where applicable.
  • Maintain awareness of new and developing legislation, regulatory policy, and technical regulatory guidance relating to Amgen products.
  • Perform regulatory research to obtain relevant histories, precedents, and other information relevant to regional product advancement.
  • Mentor and/or advise other Local Regulatory Representatives at more junior levels.
Desired Qualifications
  • Understanding of drug development.
  • Knowledge of regulatory principles.
  • Regulatory submissions experience and experience interacting with regulatory agencies, including the FDA.
  • Working knowledge of US legislation and regulations relating to medicinal products and applicable regulatory principles.
  • Comprehensive understanding of regulatory activities and how they impact other projects and processes.
  • Knowledge and experience in the US regulatory environment relevant to the product area and development stage.
  • Ability to negotiate and influence.
  • Ability to understand and communicate scientific and clinical information.
  • Ability to resolve conflicts and develop a course of action leading to a beneficial outcome.
  • Experience working with policies, procedures, and standard operating procedures.
  • Cultural awareness and sensitivity to achieve results across regional, country, and international borders.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.